Literature DB >> 16027124

Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins.

Satoko Ashikari-Hada1, Hiroko Habuchi, Yutaka Kariya, Koji Kimata.   

Abstract

Vascular endothelial growth factor (VEGF) is a family of glycoproteins with potent angiogenic activity. We reported previously that heparin has an affinity for VEGF165, the major isoform of VEGF, whereas 2-O-desulfated heparin and 6-O-desulfated heparin have weak but significant affinity (Ashikari-Hada, S., Habuchi, H., Kariya, Y., Itoh, N., Reddi, A. H., and Kimata, K. (2004) J. Biol. Chem. 279, 12346-12354). In this study, we first examined the effect of heparin and modified heparins (completely desulfated N-sulfated heparin, 2-O-desulfated heparin, and 6-O-desulfated heparin) on VEGF165-dependent mitogenic activity and tube formation on type I collagen gels of human umbilical vein endothelial cells. Both were enhanced by heparin, but not by modified heparins, suggesting that both the 2-O-sulfate group of hexuronic acid and the 6-O-sulfation group of N-sulfoglucosamine in heparin/heparan sulfate are necessary for VEGF165 activity. We then examined the activation of VEGF receptor (VEGFR) to understand the mechanism. We have made several new findings; 1) heparin yielded a 1.7-fold enhancement of VEGF165-induced phosphorylation of VEGFR-2; 2) depletion of cell surface heparan sulfate by heparinase/heparitinase treatment and preferential reduction of trisulfated disaccharide units of cell surface HS by sodium chlorate treatment resulted in the reduction of such phosphorylation, suggesting the involvement of a heparin-like domain in the phosphorylation of VEGFR-2; and 3) VEGF121, an isoform without the exon 7-encoded region, which has no capacity to bind to heparin, did not show these effects. It is therefore likely that a heparin-like domain of heparan sulfate/heparin forms a complex with VEGF165 and VEGFR-2 via the exon 7-encoded region, thereby enhancing VEGF165-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027124     DOI: 10.1074/jbc.M414581200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes.

Authors:  Claudia Bertuccio; Delma Veron; Pardeep K Aggarwal; Lawrence Holzman; Alda Tufro
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Alginate Sulfates Mitigate Binding Kinetics of Proangiogenic Growth Factors with Receptors toward Revascularization.

Authors:  John Schmidt; Min Kyung Lee; Eunkyung Ko; Jae Hyun Jeong; Luisa A DiPietro; Hyunjoon Kong
Journal:  Mol Pharm       Date:  2016-02-29       Impact factor: 4.939

Review 3.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

4.  Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability.

Authors:  Ding Xu; Mark M Fuster; Roger Lawrence; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

Review 5.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

Review 6.  In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents.

Authors:  Anne M Goodwin
Journal:  Microvasc Res       Date:  2007-06-06       Impact factor: 3.514

7.  Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.

Authors:  Tom T Chen; Alfonso Luque; Sunyoung Lee; Sean M Anderson; Tatiana Segura; M Luisa Iruela-Arispe
Journal:  J Cell Biol       Date:  2010-02-22       Impact factor: 10.539

8.  Multifunctional silk-heparin biomaterials for vascular tissue engineering applications.

Authors:  F Philipp Seib; Manuela Herklotz; Kelly A Burke; Manfred F Maitz; Carsten Werner; David L Kaplan
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

9.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

10.  HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.

Authors:  Sonia D'Souza; Weidong Yang; Dario Marchetti; Caroline Muir; Mary C Farach-Carson; Daniel D Carson
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.